Determination of optimum formulation of a novel infectious bursal disease virus (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV

by Whitfill, C. E.; Haddad, E. E.; Ricks, C. A.; Skeeles, J. K.; Newberry, L. A.; Beasley, J. N.; Andrews, P. D.; Thoma, J. A.; Wakenell, P. S.

A novel vaccine against infectious bursal disease virus (IBDV) has been developed. The new vaccine was constructed by mixing bursal disease antibody (BDA) contained in whole antiserum with live IBDV before lyophilization. To establish various formulations of BDA and IBDV, several BDA doses between 5 units and 80 units of BDA/50 pi were mixed with 100 EID(50)/50 mu l of IBDV suspension in Expt. 1; in Expt. 2, several IBDV doses between 10 EID(50)/50 mu l and 977 EID(50)/50 mu l of IBDV suspension were mixed with 24 units of BDA/50 mu l. Vaccine preparations were administered subcutaneously to the nape of I-day-old specific-pathogen-free (SPF) chicks. Safety, potency, and immunogenicity of the different vaccine formulations were evaluated using bursal weight, bursal gross examination, and IBDV antibody titer. Some bursae were examined histologically to confirm gross examinations. Several vaccine formulations were safe and efficacious and met the safety, potency, and immunogenicity criteria. A vaccine construct of 100 EID(50) mixed with 24 units of BDA was selected as the release dose. When administered at 1 day of age, the novel vaccine allows for delayed infection of the bursa until after days 6-8 of age in SPF chicks, while initiating potency and immunogenicity to an IBDV challenge. The addition of BDA to the IBDV results in a complex vaccine that allows for safer immunization in SPF birds than under administration of the vaccine virus without BDA.

Avian Diseases
Start Page
1938-4351; 0005-2086